RNA-targeting small molecules represent a class of small molecules.
Highlights
The global RNA-Targeted Small Molecules market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
RNA-targeting small molecules represent a class of small molecules, organic compounds with traditional drug properties that can bind to RNA secondary or tertiary structures and alter translation patterns, localization, and degradation.
Report Scope
This report aims to provide a comprehensive presentation of the global market for RNA-Targeted Small Molecules, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNA-Targeted Small Molecules.
The RNA-Targeted Small Molecules market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global RNA-Targeted Small Molecules market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the RNA-Targeted Small Molecules companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Accent Therapeutics
Anima Biotech Inc.
Arrakis Pharmaceuticals
Epics Therapeutics
Expansion Therapeutics
Gotham Therapeutics
H3 Biomedicine
Ribometrix
Skyhawk Therapeutics
STORM Therapeutics
Twentyeight-Seven Therapeutics
Segment by Type
mRNA Translation Regulation
RNA Splicing Modification
Direct RNA Targeting
Indirect RNA Targeting - Epitranscriptomics
Segment by Application
Hospitals
Laboratories
Phamacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RNA-Targeted Small Molecules companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global RNA-Targeted Small Molecules Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 mRNA Translation Regulation
1.2.3 RNA Splicing Modification
1.2.4 Direct RNA Targeting
1.2.5 Indirect RNA Targeting - Epitranscriptomics
1.3 Market by Application
1.3.1 Global RNA-Targeted Small Molecules Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Laboratories
1.3.4 Phamacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global RNA-Targeted Small Molecules Market Perspective (2018-2029)
2.2 RNA-Targeted Small Molecules Growth Trends by Region
2.2.1 Global RNA-Targeted Small Molecules Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 RNA-Targeted Small Molecules Historic Market Size by Region (2018-2023)
2.2.3 RNA-Targeted Small Molecules Forecasted Market Size by Region (2024-2029)
2.3 RNA-Targeted Small Molecules Market Dynamics
2.3.1 RNA-Targeted Small Molecules Industry Trends
2.3.2 RNA-Targeted Small Molecules Market Drivers
2.3.3 RNA-Targeted Small Molecules Market Challenges
2.3.4 RNA-Targeted Small Molecules Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top RNA-Targeted Small Molecules Players by Revenue
3.1.1 Global Top RNA-Targeted Small Molecules Players by Revenue (2018-2023)
3.1.2 Global RNA-Targeted Small Molecules Revenue Market Share by Players (2018-2023)
3.2 Global RNA-Targeted Small Molecules Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by RNA-Targeted Small Molecules Revenue
3.4 Global RNA-Targeted Small Molecules Market Concentration Ratio
3.4.1 Global RNA-Targeted Small Molecules Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by RNA-Targeted Small Molecules Revenue in 2022
3.5 RNA-Targeted Small Molecules Key Players Head office and Area Served
3.6 Key Players RNA-Targeted Small Molecules Product Solution and Service
3.7 Date of Enter into RNA-Targeted Small Molecules Market
3.8 Mergers & Acquisitions, Expansion Plans
4 RNA-Targeted Small Molecules Breakdown Data by Type
4.1 Global RNA-Targeted Small Molecules Historic Market Size by Type (2018-2023)
4.2 Global RNA-Targeted Small Molecules Forecasted Market Size by Type (2024-2029)
5 RNA-Targeted Small Molecules Breakdown Data by Application
5.1 Global RNA-Targeted Small Molecules Historic Market Size by Application (2018-2023)
5.2 Global RNA-Targeted Small Molecules Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America RNA-Targeted Small Molecules Market Size (2018-2029)
6.2 North America RNA-Targeted Small Molecules Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America RNA-Targeted Small Molecules Market Size by Country (2018-2023)
6.4 North America RNA-Targeted Small Molecules Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe RNA-Targeted Small Molecules Market Size (2018-2029)
7.2 Europe RNA-Targeted Small Molecules Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe RNA-Targeted Small Molecules Market Size by Country (2018-2023)
7.4 Europe RNA-Targeted Small Molecules Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific RNA-Targeted Small Molecules Market Size (2018-2029)
8.2 Asia-Pacific RNA-Targeted Small Molecules Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific RNA-Targeted Small Molecules Market Size by Region (2018-2023)
8.4 Asia-Pacific RNA-Targeted Small Molecules Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America RNA-Targeted Small Molecules Market Size (2018-2029)
9.2 Latin America RNA-Targeted Small Molecules Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America RNA-Targeted Small Molecules Market Size by Country (2018-2023)
9.4 Latin America RNA-Targeted Small Molecules Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa RNA-Targeted Small Molecules Market Size (2018-2029)
10.2 Middle East & Africa RNA-Targeted Small Molecules Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa RNA-Targeted Small Molecules Market Size by Country (2018-2023)
10.4 Middle East & Africa RNA-Targeted Small Molecules Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Accent Therapeutics
11.1.1 Accent Therapeutics Company Detail
11.1.2 Accent Therapeutics Business Overview
11.1.3 Accent Therapeutics RNA-Targeted Small Molecules Introduction
11.1.4 Accent Therapeutics Revenue in RNA-Targeted Small Molecules Business (2018-2023)
11.1.5 Accent Therapeutics Recent Development
11.2 Anima Biotech Inc.
11.2.1 Anima Biotech Inc. Company Detail
11.2.2 Anima Biotech Inc. Business Overview
11.2.3 Anima Biotech Inc. RNA-Targeted Small Molecules Introduction
11.2.4 Anima Biotech Inc. Revenue in RNA-Targeted Small Molecules Business (2018-2023)
11.2.5 Anima Biotech Inc. Recent Development
11.3 Arrakis Pharmaceuticals
11.3.1 Arrakis Pharmaceuticals Company Detail
11.3.2 Arrakis Pharmaceuticals Business Overview
11.3.3 Arrakis Pharmaceuticals RNA-Targeted Small Molecules Introduction
11.3.4 Arrakis Pharmaceuticals Revenue in RNA-Targeted Small Molecules Business (2018-2023)
11.3.5 Arrakis Pharmaceuticals Recent Development
11.4 Epics Therapeutics
11.4.1 Epics Therapeutics Company Detail
11.4.2 Epics Therapeutics Business Overview
11.4.3 Epics Therapeutics RNA-Targeted Small Molecules Introduction
11.4.4 Epics Therapeutics Revenue in RNA-Targeted Small Molecules Business (2018-2023)
11.4.5 Epics Therapeutics Recent Development
11.5 Expansion Therapeutics
11.5.1 Expansion Therapeutics Company Detail
11.5.2 Expansion Therapeutics Business Overview
11.5.3 Expansion Therapeutics RNA-Targeted Small Molecules Introduction
11.5.4 Expansion Therapeutics Revenue in RNA-Targeted Small Molecules Business (2018-2023)
11.5.5 Expansion Therapeutics Recent Development
11.6 Gotham Therapeutics
11.6.1 Gotham Therapeutics Company Detail
11.6.2 Gotham Therapeutics Business Overview
11.6.3 Gotham Therapeutics RNA-Targeted Small Molecules Introduction
11.6.4 Gotham Therapeutics Revenue in RNA-Targeted Small Molecules Business (2018-2023)
11.6.5 Gotham Therapeutics Recent Development
11.7 H3 Biomedicine
11.7.1 H3 Biomedicine Company Detail
11.7.2 H3 Biomedicine Business Overview
11.7.3 H3 Biomedicine RNA-Targeted Small Molecules Introduction
11.7.4 H3 Biomedicine Revenue in RNA-Targeted Small Molecules Business (2018-2023)
11.7.5 H3 Biomedicine Recent Development
11.8 Ribometrix
11.8.1 Ribometrix Company Detail
11.8.2 Ribometrix Business Overview
11.8.3 Ribometrix RNA-Targeted Small Molecules Introduction
11.8.4 Ribometrix Revenue in RNA-Targeted Small Molecules Business (2018-2023)
11.8.5 Ribometrix Recent Development
11.9 Skyhawk Therapeutics
11.9.1 Skyhawk Therapeutics Company Detail
11.9.2 Skyhawk Therapeutics Business Overview
11.9.3 Skyhawk Therapeutics RNA-Targeted Small Molecules Introduction
11.9.4 Skyhawk Therapeutics Revenue in RNA-Targeted Small Molecules Business (2018-2023)
11.9.5 Skyhawk Therapeutics Recent Development
11.10 STORM Therapeutics
11.10.1 STORM Therapeutics Company Detail
11.10.2 STORM Therapeutics Business Overview
11.10.3 STORM Therapeutics RNA-Targeted Small Molecules Introduction
11.10.4 STORM Therapeutics Revenue in RNA-Targeted Small Molecules Business (2018-2023)
11.10.5 STORM Therapeutics Recent Development
11.11 Twentyeight-Seven Therapeutics
11.11.1 Twentyeight-Seven Therapeutics Company Detail
11.11.2 Twentyeight-Seven Therapeutics Business Overview
11.11.3 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Introduction
11.11.4 Twentyeight-Seven Therapeutics Revenue in RNA-Targeted Small Molecules Business (2018-2023)
11.11.5 Twentyeight-Seven Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Accent Therapeutics
Anima Biotech Inc.
Arrakis Pharmaceuticals
Epics Therapeutics
Expansion Therapeutics
Gotham Therapeutics
H3 Biomedicine
Ribometrix
Skyhawk Therapeutics
STORM Therapeutics
Twentyeight-Seven Therapeutics
听
听
*If Applicable.